Q1 25 EPS
$0.92
BEAT +35.19%
Est. $0.68
Q1 25 Revenue
$13.72B
MISS 2.69%
Est. $14.09B
vs S&P Since Q1 25
-12.1%
TRAILING MARKET
PFE +17.9% vs S&P +30.0%
Market Reaction
Did PFE Beat Earnings? Q1 2025 Results
Pfizer posted a sharply mixed first quarter, delivering a meaningful earnings beat while falling short on the top line, as the lingering shadow of Paxlovid continued to weigh on overall results. Adjusted diluted EPS came in at $0.92, well ahead of th… Read more Pfizer posted a sharply mixed first quarter, delivering a meaningful earnings beat while falling short on the top line, as the lingering shadow of Paxlovid continued to weigh on overall results. Adjusted diluted EPS came in at $0.92, well ahead of the $0.68 consensus estimate and representing a 35.19% positive surprise, yet revenue of $13.71 billion trailed the $14.09 billion analyst forecast by 2.69% and slid 7.8% from a year earlier, with Paxlovid plunging 75% operationally to $491.00 million partly because a $771.00 million favorable adjustment that had inflated the prior-year comparison did not recur. Offsetting the drag, the Vyndaqel family climbed 33% operationally to $1.49 billion and Comirnaty jumped 62% operationally to $565.00 million, while aggressive cost discipline drove double-digit declines in both SI&A and R&D spending. Pfizer also discontinued its oral GLP-1 obesity candidate danuglipron, a notable pipeline setback, though management reaffirmed full-year 2025 guidance of $61.00 billion to $64.00 billion in revenue and adjusted EPS of $2.80 to $3.00, with the CFO signaling a trend toward the upper end of that earnings range.
Key Takeaways
- • Vyndaqel family growth driven by strong demand and continuing uptake in patient diagnosis
- • Comirnaty growth driven by higher U.S. market share and lower expected returns
- • Padcev growth driven by increased market share in first-line metastatic urothelial cancer
- • Nurtec ODT/Vydura growth driven by strong U.S. demand and favorable channel mix changes
- • Lorbrena growth from increased patient share in first-line ALK+ mNSCLC
- • Paxlovid decline due to non-recurrence of $771M favorable adjustment, lower COVID-19 infections, and reduced government purchases
- • IRA Medicare Part D Redesign creating unfavorable pricing impact across multiple products
- • Ongoing cost realignment program driving SI&A and R&D expense reductions
- • Favorable global income tax resolutions resulting in negative GAAP effective tax rate
PFE YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
PFE Revenue by Segment
With YoY comparisons, source: SEC Filings
PFE Revenue by Geography
With YoY comparisons, source: SEC Filings
“We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment.”
— Albert Bourla, Q1 2025 Earnings Press Release
PFE Earnings Trends
PFE vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
PFE EPS Trend
Earnings per share: estimate vs actual
PFE Revenue Trend
Quarterly revenue: estimate vs actual
PFE Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 BEAT FY | $0.57 | $0.66 | +15.79% | $17.56B | +4.09% |
| FY Full Year | $3.12 | $3.22 | +3.08% | $62.58B | +1.11% |
| Q3 25 BEAT | $0.64 | $0.87 | +36.96% | $16.65B | +0.92% |
| Q2 25 BEAT | $0.57 | $0.78 | +35.94% | $14.65B | +8.29% |
| Q1 25 BEAT | $0.68 | $0.92 | +35.19% | $13.72B | -2.69% |
| Q4 22 BEAT FY | $1.05 | $1.14 | +8.57% | $24.29B | +0.02% |
| FY Full Year | — | $6.58 | — | $100.33B | — |